Prurigo nodularis
☆ Kwiziphumo zika-2022 ze-Stiftung Warentest ezivela eJamani, ukwaneliseka kwabathengi ngeModelDerm bekungaphantsi kancinci kunokubonisana nge-telemedicine ehlawulweyo.
References
Prurigo nodularis yimeko yesikhumba ehlala ixesha elide ebonakaliswa ngamaqhuqhuva amaninzi aqinileyo kunye namaqhuqhuva, ahlala efumaneka kwiindawo ezingaphandle zeengalo nemilenze. La maqhuma angohluka ngombala ukusuka kwithoni yenyama ukuya kwepinki kwaye ayarhawuzelela kakhulu. Zinokuchaphazela abantu bayo nayiphi na iminyaka kwaye zihlala zidibaniswa nezinye iimeko zolusu ezibangela ukurhawuzelelwa okungapheliyo, njenge-atopic dermatitis. Ukhetho lonyango lubandakanya amayeza anamandla okulwa nokurhawuzelelwa, iziyobisi ezichaphazela amajoni omzimba, kunye namayeza ajolise kwinkqubo yemithambo-luvo. Ukulawula i-prurigo nodularis ngokuqhelekileyo kubandakanya unyango lwexesha elide.
Prurigo nodularis is a chronic disorder of the skin that is classically seen as multiple, firm, flesh to pink colored papules, plaques and nodules commonly located on the extensor surfaces of the extremities. The lesions are very pruritic and can occur in any age group. It is commonly associated with another disease such as atopic dermatitis or any dermatoses associated with chronic pruritus. The therapeutic approach is wide-arrayed ranging from treatments that act as - potent antipruritics, immunomodulators, and neuromodulators. Treatment in an established case is prolonged and improving patient compliance with education and counseling is important.
Prurigo nodularis is a chronic disorder of the skin that is classically seen as multiple, firm, flesh to pink colored papules, plaques and nodules commonly located on the extensor surfaces of the extremities. The lesions are very pruritic and can occur in any age group. It is commonly associated with another disease such as atopic dermatitis or any dermatoses associated with chronic pruritus. The therapeutic approach is wide-arrayed ranging from treatments that act as - potent antipruritics, immunomodulators, and neuromodulators. Treatment in an established case is prolonged and improving patient compliance with education and counseling is important.
Unyango ludla ngokubandakanya ukusebenzisa iikhrimu okanye iinaliti ze-steroids kwindawo echaphazelekayo. Kwiimeko ezinzima kakhulu okanye ezinenkani, unyango olufana nonyango olulula okanye amayeza acinezela amajoni omzimba anokufuneka. I-Thalidomide kunye ne-Lenalidomide ziinketho kwiimeko ezinzima, kodwa zinokuba neziphumo ezibi kakhulu. Unyango olutsha (opioid receptor antagonists, neurokinin-1 receptor antagonists) lubonisa isithembiso ekuphatheni i-prurigo nodularis kunye nemiphumo emibi embalwa xa kuthelekiswa ne-thalidomide okanye i-lenalidomide.
Treatment typically relies on the use of topical or intralesional steroids, though more severe or recalcitrant cases often necessitate the use of phototherapy or systemic immunosuppressives. Thalidomide and lenalidomide can both be used in severe cases; however, their toxicity profile makes them less favorable. Opioid receptor antagonists and neurokinin-1 receptor antagonists represent two novel families of therapeutic agents which may effectively treat PN with a lower toxicity profile than thalidomide or lenalidomide.
Treatment typically relies on the use of topical or intralesional steroids, though more severe or recalcitrant cases often necessitate the use of phototherapy or systemic immunosuppressives. Thalidomide and lenalidomide can both be used in severe cases; however, their toxicity profile makes them less favorable. Opioid receptor antagonists and neurokinin-1 receptor antagonists represent two novel families of therapeutic agents which may effectively treat PN with a lower toxicity profile than thalidomide or lenalidomide.
Chronic prurigo yimeko yolusu ebonakala ngokurhawuzelelwa ixesha elide (elihlala ngaphezulu kweeveki ezi-6) , izilonda zesikhumba ezinxulumene nomkrwelo, kunye nembali yokurhawuzelelwa rhoqo. Ibandakanya i-neuroinflammation kunye ne-fibrosis esikhumbeni.
Chronic prurigo (CPG) is a neuroinflammatory, fibrotic dermatosis that is defined by the presence of chronic pruritus (itch lasting longer than 6 weeks), scratch-associated pruriginous skin lesions and history of repeated scratching.
Chronic prurigo (CPG) is a neuroinflammatory, fibrotic dermatosis that is defined by the presence of chronic pruritus (itch lasting longer than 6 weeks), scratch-associated pruriginous skin lesions and history of repeated scratching.
Prurigo nodularis yingxaki yesikhumba ehlala ixesha elide ephawulwa ngamaqhuqhuva arhawuzelelayo. Asazi kanye ukuba yintoni ebangela oko, kodwa kubonakala ngathi imiba yokhuselo lomzimba kunye nemithambo-luvo idlala indima kumjikelo wokurhawuzelelwa. Okwangoku, akukho naluphi na unyango oluvunywe yi-US FDA ngokukodwa i-prurigo nodularis.
Prurigo nodularis is a long-lasting skin problem marked by itchy nodules. We don't know exactly what causes it, but it seems that immune and nerve issues play a role in the itch-scratch cycle. Right now, there aren't any treatments approved by the US FDA specifically for prurigo nodularis.
Prurigo nodularis is a long-lasting skin problem marked by itchy nodules. We don't know exactly what causes it, but it seems that immune and nerve issues play a role in the itch-scratch cycle. Right now, there aren't any treatments approved by the US FDA specifically for prurigo nodularis.
○ Unyango ― OTC Amachiza
Ukuhlamba indawo yesilonda ngesepha akuncedi kwaphela kwaye kungayenza ibe mandundu. Amafutha e-OTC steroid anokunceda ukukhulula iimpawu, kodwa ngokuqhelekileyo kufuneka asetyenziswe kwiiveki ezininzi ukuphucula. Ukuqhubeka nokuthatha i-antihistamines nako kunceda ukukhulula ukurhawuzelelwa.
#OTC steroid ointment
#OTC antihistamine
○ Unyango
#Intralesional triamcinolone injection